Stock BBLG BONE BIOLOGICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Bone Biologics Corporation

Equities

BBLG

US0980705018

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-25 EDT 		5-day change 1st Jan Change
1.21 USD -0.82% Intraday chart for Bone Biologics Corporation -18.79% -73.23%
06-20 Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion CI
05-14 Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
BU
Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion
CI
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
AQ
Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.
CI
Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.
CI
Certain Stock Options of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.
CI
Bone Biologics Announces Closing of $2.0 Million Public Offering
BU
Bone Biologics Announces Pricing of $2.0 Million Public Offering
BU
Bone Biologics Corporation Reports Progress with NB1 Clinical Program
CI
Bone Biologics Reports Progress With NB1 Clinical Program
BU
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
BU
Bone Biologics Corporation Announces Board Changes
CI
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
BU
Bone Biologics Corporation Announces the Resignation of Erick Lucera as Director
CI
Bone Biologics' 1-for-8 Reverse Stock Split Takes Effect Wednesday
MT
Bone Biologics Announces 1-for-8 Reverse Stock Split
BU
Bone Biologics Closes Common Stock Offering; Shares Fall After Hours
MT
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BBLG Stock
  4. News Bone Biologics Corporation